Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 1.88 16.05% 0.26
XBIO closed up 16.05 percent on Friday, August 16, 2019, on 1.44 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical XBIO trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 16.05%
Expansion Breakdown Bearish Swing Setup 16.05%
Narrow Range Bar Range Contraction 16.05%
New 52 Week Low Weakness 16.05%
Wide Bands Range Expansion 16.05%

Older signals for XBIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Dialysis Chronic Kidney Disease Anemia Drug Therapies Refractory Acute Myeloid Leukemia Product Candidates Growth Factors
Is XBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 54.6
52 Week Low 1.54
Average Volume 297,919
200-Day Moving Average 18.847
50-Day Moving Average 6.1678
20-Day Moving Average 2.339
10-Day Moving Average 2.055
Average True Range 0.7933
ADX 22.46
+DI 18.9356
-DI 28.5808
Chandelier Exit (Long, 3 ATRs ) 3.6201
Chandelier Exit (Short, 3 ATRs ) 3.9199
Upper Bollinger Band 3.1559
Lower Bollinger Band 1.5221
Percent B (%b) 0.22
BandWidth 69.850363
MACD Line -1.3952
MACD Signal Line -1.5704
MACD Histogram 0.1752
Fundamentals Value
Market Cap 16.39 Million
Num Shares 8.72 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -1.28
Price-to-Sales 6.14
Price-to-Book 1.60
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.44
Resistance 3 (R3) 2.39 2.17 2.34
Resistance 2 (R2) 2.17 2.03 2.19 2.31
Resistance 1 (R1) 2.02 1.94 2.10 2.07 2.28
Pivot Point 1.80 1.80 1.83 1.82 1.80
Support 1 (S1) 1.65 1.66 1.73 1.70 1.48
Support 2 (S2) 1.43 1.57 1.45 1.45
Support 3 (S3) 1.28 1.43 1.42
Support 4 (S4) 1.33